1. Pink Sheet
  2. >>Geography

Gilotrif Approval Gives Boehringer Milestone, But Can It Compete With Tarceva?

 
• By Emily Hayes

FDA approval of its first oncology drug is a victory for Boehringer Ingelheim. Now comes another challenge – a commercial battle with Roche’s Tarceva, which is firmly established across lines of therapy for EGFR-positive lung cancer patients.

Boehringer Ingelheim GMBH has passed a major milestone with the approval of its oncology drug Gilotrif (afatinib) in late-stage, non-small-cell lung cancer. Whether it can compete with Roche’s entrenched Tarceva (erlotinib) remains to be seen.

According to the company, afatinib is a once-daily, irreversible blocker of the ErbB family that specifically inhibits EGFR, HER2 and ErbB4. In contrast, Roche’s Tarceva, which is approved in the U.S

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America